Last reviewed · How we verify
NCT04400903
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
trial testing Activity Monitor in Pancreatic Ductal Adenocarcinoma in 110 participants. Terminated before completion.
30 September 2022
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 21 September 2020 |
| Primary completion | 30 September 2022 |
| Estimated completion | 30 September 2022 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Activity Monitor
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →
- Stage I Pancreatic Cancer AJCC v8 — all drugs for Stage I Pancreatic Cancer AJCC v8 →
- Stage IA Pancreatic Cancer AJCC v8 — all drugs for Stage IA Pancreatic Cancer AJCC v8 →
- Stage IB Pancreatic Cancer AJCC v8 — all drugs for Stage IB Pancreatic Cancer AJCC v8 →
Sponsor
OHSU Knight Cancer Institute
Who can join
Adults 50 to 75, any sex, with Pancreatic Ductal Adenocarcinoma or Stage I Pancreatic Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study examines heart rate monitoring variability for the early detection of pancreatic cancer. Pancreatic cancer is a very difficult disease to detect early. This study is being done to observe the heart rate variability in patients with pancreatic cancer compared to undiagnosed individuals with increased risk of developing pancreatic cancer. This may help researchers determine if pancreatic occurrences/recurrences (chance of coming back) can be detected sooner through monitoring heart rate and activity.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A review of physical activity in pancreatic ductal adenocarcinoma: Epidemiology, intervention, animal models, and clinical trials.
Hsueh HY, Pita-Grisanti V, Gumpper-Fedus K, Lahooti A, et al · · 2022 · cited 17× · PMID 34750076 · DOI 10.1016/j.pan.2021.10.004 -
Evidence of sex differences in cancer-related cardiac complications in mouse models of pancreatic and liver cancer.
Gams A, Nevarez A, Perkail S, Venegas A, et al · · 2023 · cited 3× · PMID 37102225 · DOI 10.14814/phy2.15672
Verify or expand the search:
- PubMed search for NCT04400903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Activity Monitor
Trials testing the same drug.
- NCT05498415 — Feasibility, Acceptability, and Efficacy of the Sleep Move Stand Study · NA · completed
- NCT05053113 — Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive Women · NA · recruiting
- NCT04254172 — A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy · terminated
- NCT04889131 — Yoga for Seniors · NA · terminated
- NCT03971266 — Movement and Fitness Trackers in Determining Performance Status · NA · terminated
Other recruiting trials for Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
- NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04400903 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 22 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04400903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing